Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Zavicefta

- PMLiVE

Two new cancer drugs recommended in Europe

CHMP backing for Roche's Erivedge and Astellas' Xtandi

- PMLiVE

EMA refuses to back Pfizer’s Xeljanz in rheumatoid arthritis

Surprise after approvals in US and Japan

- PMLiVE

European drug applications ‘stable but more complex in 2012’

Despite austerity measures, EMA's annual report shows signs of biopharma resilience

- PMLiVE

EMA recommends heart risk restriction for Servier’s Protelos

Use of osteoporosis drug likely to be further tightened up

- PMLiVE

Sanofi’s four-strain flu vaccine Vaxigrip under review in EU

Pharma company also launches production of ingredient for malaria drug

- PMLiVE

Clinical trials for EMA-submitted medicines move away from US and Europe

Most trial patients for drug marketing applications to EMA now come from rest of the world

- PMLiVE

Pfizer enters $210m+ nanomedicines deal with Bind

Will use Accurin technology to develop highly selective medicines

- PMLiVE

Pfizer partners with hospital to research medicines for children

Children’s Hospital of Philadelphia joins CTI translational research network

Agneta Brandt joins EMA as head of infrastructure

Joins as company prepares to move offices

- PMLiVE

Pfizer’s Bosulif gets conditional green light for CML in Europe

Follows US approval last year

- PMLiVE

EMA launches diabetes drugs safety review

Will investigate pancreatitis risks in two major drug classes

- PMLiVE

NICE: Pfizer’s lung cancer drug Xalkori too expensive for NHS

Pharma company says NICE's data demands need to take ethics into account

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links